Harmony Biosciences (HRMY) reported $868M in revenue for fiscal 2025, +21.5% year on year. That ranks #1862 by revenue among 2853 SEC filers and #173 in Healthcare. Net income was $159M, a net margin of 18.3%. Revenue has grown 129.2% a year on average since 2019 ($6.0M then). The fiscal 2025 balance sheet shows $1.3B in total assets, $753M in cash and $144M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $868M | +21.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $670M | +20.1% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $208M | +9.2% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $159M | +9.1% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $348M | +58.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $310,000 | −73.1% | FY20252025-12-31 |
| Total assetsAssets | $1.3B | +27.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $870M | +32.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $753M | +66.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $144M | −11.9% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $215M | $32.5M | Open → |
| Q2 20262026-06-30 | $261M | $75.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Harmony Biosciences Holdings, Inc.
- Ticker
- HRMY
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001802665
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Biocryst PharmaceuticalsBCRX | $875M | $264M |
| Warby ParkerWRBY | $872M | $1.6M |
| NeogenNEOG | $870M | −$7.9M |
| Harmony BiosciencesHRMY | $868M | $159M |
| Innovage HoldingINNV | $854M | −$30.3M |
| Arrowhead PharmaceuticalsARWR | $829M | −$1.6M |
| Myriad GeneticsMYGN | $825M | −$366M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Harmony Biosciences — Key figures |url=https://companiesranked.com/en/company/harmony-biosciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Harmony Biosciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/harmony-biosciencesBibTeX
@misc{companiesranked-en-company-harmony-biosciences-2026,
author = {{CompaniesRanked}},
title = {{Harmony Biosciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/harmony-biosciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-018859 · February 24, 2026
{{cite web |title=Harmony Biosciences — Key figures — 10-K (0001104659-26-018859) |url=https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.